By
Wandercraft announced today that it enrolled the first participants in a clinical trial evaluating its Personal Exoskeleton system
The Personal Exoskeleton in use. [Image courtesy of Wandercraft]
The company describes the Personal Exoskeleton as the world’s first self-balancing exoskeleton designed for personal use. It says the first enrollments in the study mark a critical step in assessing how advanced robotic technology can enable independent, upright mobility for individuals with spinal cord injuries (SCI).
Wandercraft announced the launch of this trial last month. The company already offers the FDA-cleared Atalante X exoskeleton for individuals with spinal cord injuries (SCIs). Atalante X, a self-balancing robotic exoskeleton, enables those with limited mobility to stand up and walk again.
Engineered to adapt to users’ movements in real time, the Personal Exoskeleton ensures smooth walking across diverse surfaces. These surfaces include carpet, concrete and tile. The company said it designed the device to go beyond mobility. Its self-balancing design could improve mobility and walking independence in users’ everyday lives at home and in the community.
The study evaluates latest exoskeleton system — used during last year’s Olympic torch-lighting ceremony — for safety and effectiveness in individuals with spinal cord injuries (SCI). Investigators are conducting the study at James J. Peters VA Medical Center in Bronx, New York, and the Kessler Foundation in West Orange, New Jersey.
“Enrolling the first participant in this trial is a major step toward bringing our technologies across the entire continuum of care,” said Matthieu Masselin, CEO of Wandercraft. “By gathering real-world data from individuals with SCI, we are advancing our mission to empower people to walk again in their everyday lives.”
